Severe pulmonary infections remain a leading cause of acute respiratory distress syndrome and critical illness worldwide. During severe pulmonary inflammation, pathological microvascular hyperpermeability and alveolar flooding drive rapid respiratory compromise. Consequently, protecting the pulmonary endothelial barrier is a crucial therapeutic strategy to mitigate alveolar-capillary barrier breakdown and prevent pulmonary edema. Recent translational research has identified key phytoconstituents that preserve vascular integrity during acute infectious insults. In particular, modern molecular investigations into traditional multi-herb preparations provide significant insights into targeted vascular stabilization. This article reviews groundbreaking findings identifying ginsenoside Rb1 from the Qingfei Jiedu Huatan Formula as a potent vascular protector that modulates plasminogen activator inhibitor-1 (PAI-1) and restores junctional proteins in severe pneumonia models.

Pathophysiology of Pulmonary Endothelial Barrier Disruption

In acute pneumonia, bacterial toxins such as lipopolysaccharide (LPS) and host-derived cytokines trigger extensive microvascular damage. Specifically, pathogens like Klebsiella pneumoniae stimulate alveolar macrophages and recruitment of polymorphonuclear neutrophils. Consequently, activated neutrophils release reactive oxygen species, proteases, and pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α. This hyperinflammatory cascade rapidly destabilizes the vascular endothelium lining the pulmonary capillaries.

Under physiological conditions, vascular endothelial-cadherin (VE-cadherin) forms essential adherens junctions that anchor adjacent endothelial cells. However, profound systemic and local inflammation accelerates VE-cadherin internalization and degradation. As a result, microvascular permeability increases drastically, allowing protein-rich fluid and inflammatory cells to leak into the interstitial and alveolar spaces. This capillary extravasation elevates the lung wet/dry weight ratio and impairs gas exchange. Therefore, preventing adherens junction disassembly represents an indispensable approach to preserving pulmonary mechanics. By understanding the intricate molecular drivers of endothelial compromise, clinicians and researchers can identify novel therapeutic targets to intercept severe pulmonary edema before irreversible respiratory failure develops.

Transcriptomic Profiling and LC-MS Identification of Bioactive Constituents

To identify therapeutic candidates for pulmonary vascular preservation, researchers recently investigated Qingfei Jiedu Huatan Formula (QJHF). Historically, clinicians utilized this herbal preparation for severe respiratory syndromes characterized by phlegm-heat obstruction. In a rigorous experimental investigation, scientists employed liquid chromatography-mass spectrometry (LC-MS) serum pharmacochemistry combined with single-cell RNA sequencing to delineate its pharmacodynamic actions.

The single-cell transcriptomic data demonstrated that QJHF comprehensively suppressed inflammatory signaling pathways and markedly reinforced endothelial barrier genes in lung tissue. In mouse models challenged with Klebsiella pneumoniae or LPS, QJHF substantially decreased neutrophil accumulation, reduced myeloperoxidase activity, and lowered pro-inflammatory cytokine expression. Furthermore, the formula reduced Evans blue extravasation and reversed pulmonary edema. Through integrated serum profiling and network pharmacology, investigators isolated ten major absorbed bioavailable constituents. Among these candidate compounds, ginsenoside Rb1 emerged as the primary bioactive driver responsible for sustaining endothelial integrity. This analytical approach proves how advanced chemical profiling can systematically clarify the molecular mechanisms of complex phytotherapeutic mixtures.

Ginsenoside Rb1 and Pulmonary Endothelial Barrier Stabilization

Ginsenoside Rb1 (G-Rb1) is a principal protopanaxadiol saponin known for its broad cytoprotective and anti-inflammatory properties. In the context of acute infectious lung injury, G-Rb1 demonstrates targeted efficacy in maintaining the pulmonary endothelial barrier. When tested in lipopolysaccharide-induced human umbilical vein endothelial cells (HUVEC), G-Rb1 administration significantly prevented inflammatory hyperpermeability.

Furthermore, in vivo experiments confirmed that purified G-Rb1 independently replicated the protective actions of the full herbal formula. Mice treated with G-Rb1 exhibited diminished lung injury scores, reduced inflammatory cytokine release, and marked reduction in alveolar protein leakage. Importantly, G-Rb1 treatment restored the expression and membrane localization of VE-cadherin, thereby preventing junctional disassembly under severe endotoxin stress. Additionally, G-Rb1 reduced the transmigration of activated neutrophils into the pulmonary parenchyma. This dual action—dampening local inflammatory recruitment while structurally consolidating endothelial adherens junctions—highlights G-Rb1 as a potent pharmacological candidate for sepsis- and pneumonia-induced capillary leak syndromes.

Targeting PAI-1: Molecular Mechanism of Barrier Restoration

To uncover how ginsenoside Rb1 fortifies endothelial junctions, investigators performed extensive molecular target identification. They pinpointed plasminogen activator inhibitor-1 (PAI-1, also known as SERPINE1) as the direct molecular target of G-Rb1. PAI-1 is a key serine protease inhibitor that regulates fibrinolysis, cell adhesion, and extracellular matrix remodeling. Under inflammatory stress, pathological elevation of PAI-1 disrupts endothelial junction dynamics and promotes vascular hyperpermeability.

The direct binding interaction between G-Rb1 and PAI-1 was validated through molecular dynamics simulations, cellular thermal shift assays (CETSA), and surface plasmon resonance (SPR) analysis. These biophysical assays confirmed high-affinity, stable binding between the compound and the PAI-1 protein. Mechanistically, G-Rb1 engagement suppresses aberrant PAI-1 signaling, thereby averting VE-cadherin internalization and maintaining cell-cell adhesion. Crucially, when researchers experimentally induced PAI-1 overexpression in endothelial models, the barrier-protective effects of G-Rb1 were completely abolished. This finding provides conclusive functional proof that PAI-1 inhibition is the primary mechanism through which G-Rb1 preserves vascular integrity.

Translational Potential and Future Directions in Critical Care

Severe pneumonia and secondary acute respiratory distress syndrome represent enormous clinical challenges in intensive care units worldwide, particularly due to the lack of targeted endothelial-stabilizing pharmacotherapies. While supportive mechanical ventilation and antimicrobial agents remain standard care, they do not directly repair disrupted endothelial junctions. Therefore, pharmacological strategies that target vascular leak pathways provide a valuable complementary therapeutic angle.

Targeting the PAI-1/VE-cadherin axis using defined natural small molecules like ginsenoside Rb1 opens promising avenues for drug development. Moreover, identifying precise molecular targets transforms empirical herbal therapeutics into evidence-based modern pharmacology. Nevertheless, significant translational steps remain necessary before clinical adoption. Clinicians and pharmacologists must establish human pharmacokinetic profiles, optimal therapeutic windows, bio-distribution characteristics, and potential drug-drug interactions with standard critical care medications. Future randomized controlled trials evaluating standardized formulations will ultimately determine whether these endothelial-protective mechanisms translate into reduced ventilator days and improved survival in severe respiratory infections.

Frequently Asked Questions

What is the role of the pulmonary endothelial barrier in severe pneumonia?

The pulmonary vascular endothelial barrier maintains a strictly regulated semi-permeable boundary between the bloodstream and alveolar airspaces. In severe pneumonia, bacterial pathogens and inflammatory cytokines disrupt endothelial cell junctions, particularly VE-cadherin complexes. Consequently, this barrier breakdown causes massive vascular leakage, extensive neutrophil extravasation, and alveolar flooding. These pathological changes severely compromise arterial oxygenation and accelerate the progression of acute respiratory distress syndrome in critically ill patients.

How does ginsenoside Rb1 protect against pulmonary vascular leakage?

Ginsenoside Rb1 directly binds and inhibits plasminogen activator inhibitor-1 (PAI-1), a protein elevated during acute inflammatory conditions. By suppressing aberrant PAI-1 activity, ginsenoside Rb1 prevents the internalization and degradation of VE-cadherin. As a result, it preserves endothelial adherens junctions, attenuates microvascular hyperpermeability, reduces pulmonary edema, and limits excessive inflammatory cell infiltration into injured lung tissues during severe pneumonia.

Why is targeting PAI-1 significant for managing acute lung injury?

Plasminogen activator inhibitor-1 (PAI-1) plays a pivotal pathological role in vascular inflammation and barrier breakdown. Elevated PAI-1 levels correlate with endothelial dysfunction, junctional disassembly, and poor outcomes in acute lung injury. Therefore, selectively targeting PAI-1 with small molecules restores VE-cadherin expression and preserves vascular integrity. This specific mechanism provides a promising host-directed therapeutic approach alongside traditional antimicrobial therapies in critical care settings.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Zhao P et al. LC-MS-Guided Identification of Bioactive Constituents in Qingfei Jiedu Huatan Formula Reveals Ginsenoside Rb1 as an Endothelial Barrier-Protective Compound Targeting PAI-1 in Pneumonia. Phytochem Anal. 2026 Aug 22. doi: 10.1002/pca.70087. PMID: 42630101.
2. Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by hypoxia and inflammation: Implication for pulmonary vascular pathology. Thromb Haemost. 2003;89(4):666-673.
3. Komarova YA, Kruse K, Mehta D, Malik AB. Protein Interactions at Endothelial Junctions and Signaling Mechanisms Regulating Endothelial Permeability. Circ Res. 2017;120(1):179-206.